Role of oral extended-spectrum cephems in the treatment of acute exacerbation of chronic bronchitis

Diagnostic Microbiology and Infectious Disease

Volumn 57, Issue 3 SUPPL., 2007, Pages

  Anzueto, Antonio ^a   Bishai, William R ^b   Pottumarthy, Sudha ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Human Services   (United States)

Author keywords

AECB; Oral cephems

Indexed keywords

AMPICILLIN; AZITHROMYCIN; CEFACLOR; CEFDINIR; CEFDITOREN; CEFIXIME; CEPHEM DERIVATIVE; COTRIMOXAZOLE; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN G;

ARTICLE; BRONCHITIS; CLINICAL TRIAL; DISEASE EXACERBATION; HAEMOPHILUS INFLUENZAE; HUMAN; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BRONCHITIS, CHRONIC; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 33847369576     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2006.12.003     Document Type: Article

References (43)

1. Albrich W.C., Monnet D.L., and Harbarth S. Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Emerg. Infect. Dis. 10 (2004) 514-517
2. Alvarez-Sala J.-.L., Kardos P., Martinez-Beltran J., Coronel P., Aguilar L., and Group C.A.W. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob. Agents Chemother. 50 (2006) 1762-1767
3. American Lung Association. Epidemiology and statistics unit, research and program services. Trends in chronic bronchitis and emphysema: morbidity and morality (2006). http://www.lungusa.org/atf/cf/{7A8D42C2-FCCA-4604-8ADE-7F5D5E762256}/COP D06.PDF (Accessed September 2006)
4. Anthonisen N.R., Manfreda J., Warren C.P., Hershfield E.S., Harding G.K., and Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 106 (1987) 196-204
5. Anzueto A. The importance of appropriate treatment of chronic bronchitis. Am. J. Manag. Care 6 (2000) S437-S441
6. Anzeuto A, Bishai WR, Pottumarthy S (2006) Role of oral extended-spectrum cephems in the treatment of acute exacerbation of chronic bronchitis: focus on cefdinir (in this supplement).
7. Balter M.S., La Forge J., Low D.E., Mandell L., and Grossman R.F. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can. Respir. J. 10 Suppl B (2003) 3B-32B
8. Baughman R.P., and Pina E. Infections in acute exacerbation of chronic bronchitis: what are they and how do we know?. Semin. Respir. Crit. Care Med. 21 (2000) 87-96
9. Brunton S., Carmichael B.P., Colgan R., Feeney A.S., Fendrick A.M., Quintiliani R., and Scott G. Acute exacerbation of chronic bronchitis: a primary care consensus guideline. Am. J. Manag. Care 10 (2004) 689-696
10. Celli B.R., and MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 23 (2004) 932-946
11. Chatterjee A., Moland E.S., and Thomson K.S. Cefdinir: an oral alternative to parenteral cephems. Diagn. Microbiol. Infect. Dis. 51 (2005) 259-264
12. Chen D.K., McGeer A., de Azavedo J.C., and Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N. Engl. J. Med. 341 (1999) 233-239
13. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest 127 (2005) 2231-2236
14. Cook P.J., Andrews J.M., Wise R., and Honeybourne D. Distribution of cefdinir, a third generation cephalosporin antibiotic, in serum and pulmonary compartments. J. Antimicrob. Chemother. 37 (1996) 331-339
15. Donner C.F. Acute exacerbation of chronic bronchitis: need for an evidence-based approach. Pulm. Pharmacol. Ther. 19 Suppl 1 (2006) 4-10
16. Fogarty C.M., Bettis R.B., Griffin T.J., Keyserling C.H., Nemeth M.A., and Tack K.J. Comparison of a 5 day regimen of cefdinir with a 10 day regimen of cefprozil for treatment of acute exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 45 (2000) 851-858
17. GOLD. Global initiative for chronic obstructive lung disease guidelines. Available at: (2006). http://goldcopd.com/GuidelinesResources.asp?I1=2&I2=0 (Accessed November 13, 2006)
18. Guay D.R. Cefdinir: an advanced-generation, broad-spectrum oral cephalosporin. Clin. Ther. 24 (2002) 473-489
19. Henry D.C., Poling T.L., Bettis R.B., Hunt B.J., Cyganowski M., and Hom R.C. A double-blind randomized study of cefditoren vs cefuroxime for AECB. J. Respir. Dis. 22 Suppl 8 (2001) 69S-74S
20. Hillberg R.E. The role of infection in acute exacerbations of chronic obstructive pulmonary disease. Am. J. Manag. Care 6 (2000) S427-S436
21. Jacobs M.R., Felmingham D., Appelbaum P.C., and Gruneberg R.N. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 52 (2003) 229-246
22. Johnson D.M., Biedenbach D.J., Beach M.L., Pfaller M.A., and Jones R.N. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. Diagn. Microbiol. Infect. Dis. 37 (2000) 99-105
23. Johnson D.M., Stilwell M.G., Fritsche T.R., and Jones R.N. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003). Diagn. Microbiol. Infect. Dis. 56 (2006) 69-74
24. Kim N., and Leeper Jr. K.V. Epidemiology of chronic bronchitis and acute infective exacerbations of chronic bronchitis. Semin. Respir. Crit. Care Med. 21 (2000) 73-78
25. Labia R., and Morand A. Interaction of cefdinir with β-lactamases. Drugs Exp. Clin. Res. 20 (1994) 43-48
26. Lister P.D. Emerging resistance problems among respiratory tract pathogens. Am. J. Manag. Care 6 (2000) S409-S418
27. Mannino D.M. Epidemiology and global impact of chronic obstructive pulmonary disease. Semin. Respir. Crit. Care Med. 26 (2005) 204-210
28. Martinez F.J., and Anzueto A. Appropriate outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Am. J. Med. 118 Suppl 7A (2005) 39S-44S
29. McCormick A.W., Whitney C.G., Farley M.M., Lynfield R., Harrison L.H., Bennett N.M., Schaffner W., Reingold A., Hadler J., Cieslak P., Samore M.H., and Lipsitch M. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat. Med. 9 (2003) 424-430
30. Mensa J., and Trilla A. Should patients with acute exacerbation of chronic bronchitis be treated with antibiotics? Advantages of the use of fluoroquinolones. Clin. Microbiol. Infect. 12 (2006) 42-54
31. Mera R.M., Miller L.A., Daniels J.J., Weil J.G., and White A.R. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States over a 10-year period: Alexander Project. Diagn. Microbiol. Infect. Dis. 51 (2005) 195-200
32. National Heart Lung and Blood Institute. Morbidity and morality chartbook on cardiovascular, lung and blood diseases (2004). http://www.nhlbi.nih.gov/resources/docs/04_chtbk.pdf (Accessed September 2006)
33. NCCLS. National Committee for Clinical Laboratory Standards. M100-S13, Performance Standards for Antimicrobial Susceptibility Testing, 13th Informational Supplement (2003), NCCLS, Wayne, PA
34. Package insert. Omnicef (cefdinir) (2006), Abbott Laboratories, North Chicago, IL. http://www.rxabbott.com/pdf/omnicef.PDF (Accessed September 2006)
35. Paster R.Z., McAdoo M.A., Keyserling C.H., Nemeth M.A., Tack K.J., and Griffin T.J. A comparison of a five-day regimen of cefdinir with a seven-day regimen of loracarbef for the treatment of acute exacerbations of chronic bronchitis. Int. J. Clin. Pract. 54 (2000) 293-299
36. Perry C.M., and Scott L.J. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections. Drugs 64 (2004) 1433-1464
37. Sader H.S., Fritsche T.R., Mutnick A.H., and Jones R.N. Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002). Diagn. Microbiol. Infect. Dis. 47 (2003) 515-525
38. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 117 (2000) 380S-385S
39. Sethi S. Pathogenesis and treatment of acute exacerbations of chronic obstructive pulmonary disease. Semin. Respir. Crit. Care Med. 26 (2005) 192-203
40. Sethi S., Evans N., Grant B.J., and Murphy T.F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 347 (2002) 465-471
41. Slama T.G., Amin A., Brunton S.A., File Jr. T.M., Milkovich G., Rodvold K.A., Sahm D.F., Varon J., and Weiland Jr. D. A clinician's guide to the appropriate and accurate use of antibiotics: the Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteria. Am. J. Med. 118 Suppl 7A (2005) 1S-6S
42. Van Herwaarden C.L., Langan C.E., Siemon G., Rudolph C., Keyserling C.H., Nemeth M.A., and Tack K.J. International study comparing cefdinir and cefuroxime axetil in the treatment of patients with acute exacerbation of chronic bronchitis. Int. J. Infect. Dis. 4 (2000) 26-33
43. Wellington K., and Curran M.P. Cefditoren pivoxil: a review of its use in the treatment of bacterial infections. Drugs 64 (2004) 2597-2618